Compugen Ltd. (NASDAQ:CGEN) Stock Rated "Buy" by Wall Street Brokerages

Key Points

• Analysts give Compugen a consensus “Buy” rating: Three of five analysts rate the stock “Buy,” one says “Strong Buy,” and one says “Hold.” The average 12-month price target is $5.00.
• Compugen reported quarterly earnings per share of -$0.06, beating the consensus estimate of -$0.08, while revenue of $3.82 million exceeded analysts’ $1.28 million estimate.
• CGEN opened at $2.09, within its 12-month range of $1.43 to $3.23; institutional investors and hedge funds own 12.22% of the stock.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) has received a consensus rating of "Buy" from the five analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $5.00.

A number of equities research analysts recently issued reports on CGEN shares. Weiss Ratings restated a "hold (c-)" rating on shares of Compugen in a report on Tuesday, November 3rd. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price target on shares of Compugen in a research note on Monday, October 12th.

Compugen Price Performance

CGEN opened at $2.09 on Thursday. The stock has a market capitalization of $197.62 million, a price-to-earnings ratio of 5.36 and a beta of 2.85. The business has a 50-day moving average of $2.22 and a two-hundred day moving average of $2.29. Compugen has a 12 month low of $1.43 and a 12 month high of $3.23.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. Compugen had a net margin of 47.90% and a return on equity of 39.30%. The business had revenue of $3.82 million for the quarter, compared to analyst estimates of $1.28 million. During the same period in the prior year, the firm posted ($0.07) EPS. Equities research analysts anticipate that Compugen will post -0.28 earnings per share for the current year.

Institutional Trading of Compugen

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Joel Isaacson & Co. LLC raised its position in shares of Compugen by 291.7% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company's stock worth $112,000 after buying an additional 35,000 shares during the period. WINTON GROUP Ltd boosted its holdings in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company's stock valued at $422,000 after acquiring an additional 40,614 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Compugen during the second quarter valued at about $110,000. Glenmede Trust Co. NA grew its position in Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 22,500 shares during the period. Finally, Renaissance Technologies LLC grew its position in Compugen by 12.1% during the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company's stock valued at $3,478,000 after acquiring an additional 176,088 shares during the period. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. NASDAQ: CGEN is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines. Compugen's research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.